Endocrine Abstracts

Introduction: Faslodex (Fulvestrant) is a novel antiestrogen, which has been demonstrated to have clinical efficacy in metastatic breast cancer. It is thought to mediate it's effects by downregulating ER expression. ER-alpha and ER-beta function as transcription factors to modulate genes relevant to breast cancer progression. Both interact with nuclear regulatory proteins to enhance or inhibit transcription. We hypothesized that Faslodex may modulate the recruitment and intera...

ER-alpha and ER-beta function as transcription factors to modulate expression of target genes. Both interact with nuclear regulatory proteins to enhance or inhibit transcription. We hypothesized that these co-regulators are expressed in breast cancer tissue and may be differentially regulated by estrogen and tamoxifen.ER-alpha, ER-beta, the co-activator SRC-1, and the co-repressor SMRT were localized within breast tissue by immunohistochemistry, and the spatial co-expressi...

ER-alpha and ER-beta function as transcription factors to modulate expression of target genes. Both interact with nuclear regulatory proteins to enhance or inhibit transcription. We hypothesized that these co-regulators are expressed in breast cancer tissue and may be differentially regulated by estrogen and tamoxifen.ER-alpha, ER-beta, the co-activator SRC-1, and the co-repressor SMRT were localized within breast tissue by immunohistochemistry, and the ...

The estrogen receptor is encoded by two genes (ER-alpha and ER-beta). Both function as transcription factors to modulate expression of target genes. ER-alpha has been shown to interact with co-regulators to enhance or inhibit transcription in vitro. We hypothesised that the existence of these co-regulators contribute to the differing clinical response of patients to treatment with the anti-estrogen four hydroxytamoxifen (4-HOT). The aim of this project was to localise ER-alpha...

The relationship between serum TSH and thyroid autoantibodies is frequently used to classify thyroid disease both overt and subclinical. Further debate has centred on the validity of the cutoff point for serum TSH elevation (generally between 4-5 mU/l) which it has been suggested is inappropriately high. The significance of the presence of thyroid autoantibodies (hereafter termed antibody positivity) in extrathyroidal disease is unclear but an increased prevalence has been rep...